BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 34011618)

  • 41. Non-uniform
    Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
    Front Immunol; 2019; 10():2489. PubMed ID: 31736946
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.
    Raberahona M; Wackenheim C; Germi R; Carré M; Bulabois CE; Thiébaut A; Lupo J; Semenova T; Cahn JY; Morand P; Epaulard O
    Transpl Infect Dis; 2016 Dec; 18(6):889-895. PubMed ID: 27696681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
    Mahadeo KM; Baiocchi R; Beitinjaneh A; Chaganti S; Choquet S; Dierickx D; Dinavahi R; Duan X; Gamelin L; Ghobadi A; Guzman-Becerra N; Joshi M; Mehta A; Navarro WH; Nikiforow S; O'Reilly RJ; Reshef R; Ruiz F; Spindler T; Prockop S
    Lancet Oncol; 2024 Mar; 25(3):376-387. PubMed ID: 38309282
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients.
    Barker JN; Martin PL; Coad JE; DeFor T; Trigg ME; Kurtzberg J; Weisdorf DJ; Wagner J
    Biol Blood Marrow Transplant; 2001; 7(7):395-9. PubMed ID: 11529490
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
    Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
    Front Immunol; 2020; 11():1231. PubMed ID: 32625211
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful Blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: A case report and literature review.
    Chen S; An L; Han J; Zheng X; Zhang X; Li G; Zhang Y; Cao W; Lv M; Yang D; Jiang E; Pang A; Feng S
    Transpl Immunol; 2023 Oct; 80():101895. PubMed ID: 37414267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Post-transplant lymphoproliferative disease in children, adolescents, and young adults.
    Gross TG; Rubinstein JD
    Hematol Oncol; 2023 Jun; 41 Suppl 1():48-56. PubMed ID: 37294957
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
    Ru Y; Chen J; Wu D
    Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH).
    García-Cadenas I; Yáñez L; Jarque I; Martino R; Pérez-Simón JA; Valcárcel D; Sanz J; Bermúdez A; Muñoz C; Calderón-Cabrera C; García E; Alonso L; Suárez-Lledó M; González Vicent M; Heras I; Viguria MC; Batlle M; Vázquez L; López J; Solano C;
    Eur J Haematol; 2019 Jun; 102(6):465-471. PubMed ID: 30828868
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lymphocyte subset at time of Epstein-Barr viremia post-allogeneic hematopoietic stem cell transplantation in children may predict development of post-transplant lymphoproliferative disease: CD8:CD20 ratio as a sensitive predictor.
    Althubaiti S; Ali S; Renzi S; Krueger J; Chiang KY; Schechter T; Punnett A; Ali M
    Pediatr Transplant; 2019 Dec; 23(8):e13574. PubMed ID: 31496046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes.
    Xu LP; Zhang CL; Mo XD; Zhang XH; Chen H; Han W; Chen YH; Wang Y; Yan CH; Wang JZ; Wang FR; Zhao T; Liu YR; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2185-2191. PubMed ID: 26253005
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The efficacy and safety of donor lymphocyte infusion to treat Epstein-Barr virus associated lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
    Xu LP; Liu DH; Liu KY; Chen H; Han W; Wang Y; Wang J; Shi HX; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):955-8. PubMed ID: 21211211
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.
    Ali S; AlThubaiti S; Renzi S; Krueger J; Chiang KY; Naqvi A; Schechter T; Punnett A; Ali M
    Pediatr Transplant; 2019 Feb; 23(1):e13319. PubMed ID: 30417487
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ofatumumab for Post-Transplant Lymphoproliferative Disorder.
    Seshadri M; Crane GM; Gergis U
    Hematol Oncol Stem Cell Ther; 2022 Mar; 15(1):68-73. PubMed ID: 32413419
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?
    Solano C; Mateo EM; Pérez A; Talaya A; Terol MJ; Albert E; Giménez E; Vinuesa V; Piñana JL; Boluda JCH; Navarro D
    J Clin Virol; 2017 Dec; 97():26-32. PubMed ID: 29096390
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.
    Nash RA; Dansey R; Storek J; Georges GE; Bowen JD; Holmberg LA; Kraft GH; Mayes MD; McDonagh KT; Chen CS; Dipersio J; Lemaistre CF; Pavletic S; Sullivan KM; Sunderhaus J; Furst DE; McSweeney PA
    Biol Blood Marrow Transplant; 2003 Sep; 9(9):583-91. PubMed ID: 14506660
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Epstein-Barr virus-associated post-transplant lymphoproliferative disorder diagnosed by the episode of intestinal perforation following allogeneic hematopoietic stem cell transplantation].
    Aimoto M; Yamane T; Inoue A; Momose D; Moriguchi-Aimoto R; Wada-Inoue E; Okamoto S; Koh H; Nakane T; Takeoka Y; Akahori-Nakamae M; Nishiki-Kosaka S; Terada Y; Nakamae H; Koh KR; Nakao T; Ohsawa M; Hino M
    Rinsho Ketsueki; 2010 Dec; 51(12):1775-80. PubMed ID: 21258188
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical Analysis of Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients].
    Yan HM; Zheng XL; Zhu L; Ding L; Han DM; Liu J; Xue M; Li S; Wang HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1224-1229. PubMed ID: 35981389
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
    Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Imadome KI; Mizukami Y; Okumura T
    Medicine (Baltimore); 2022 Mar; 101(12):e29055. PubMed ID: 35357349
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epstein-Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation.
    Takamatsu H; Araki R; Nishimura R; Yachie A; Espinoza JL; Okumura H; Yoshida T; Kuzushima K; Nakao S
    J Clin Virol; 2016 Jul; 80():82-6. PubMed ID: 27218416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.